Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
CT ORDER

CT ORDER

 View HTML
9999999997-16-024629.pdf
EFFECT

EFFECT

 View HTML
9999999995-16-005229.pdf
9999999995-16-005229.rtf
9999999995-16-005229.xls
10-Q/A

Amendment to a previously filed 10-Q

 View HTML
0001558370-16-006732.pdf
0001558370-16-006732.rtf
0001558370-16-006732.xls
S-3/A

Pre-effective amendment to an S-3 filing

 View HTML
0001558370-16-006734.pdf
0001558370-16-006734.rtf
0001558370-16-006734.xls
CORRESP

CORRESP

 View HTML
0001558370-16-006736.pdf
0001558370-16-006736.rtf
0001558370-16-006736.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-026949.pdf
0001179110-16-026949.rtf
0001179110-16-026949.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-026948.pdf
0001179110-16-026948.rtf
0001179110-16-026948.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-026954.pdf
0001179110-16-026954.rtf
0001179110-16-026954.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-026952.pdf
0001179110-16-026952.rtf
0001179110-16-026952.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-026953.pdf
0001179110-16-026953.rtf
0001179110-16-026953.xls